Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology and CVMD


The US Orphan Drug Act was developed in the 1980s to facilitate the development and commercialization of drugs to treat rare diseases, termed orphan drugs. At that time, few people could have predicted the massive step forward that oncology research would take in characterizing the many heterogeneous forms of the disease, and how this would impact on orphan drug research. As ever increasing numbers of treatments are designated orphan status, Crown Bioscience reviews whether the FDA has given a home to too many orphans.

Read more

Crown Bioscience are proud to be thought leaders and innovators in our field, and at the AACR in April we showcased a range of scientific and booth posters at the forefront of augmented reality technology. All of our posters were enhanced using the latest Layar technology, which allowed anyone with a smartphone or iPad to watch a detailed video explanation about the science and products behind each poster. At ASCO in Chicago we did the same and at ADA in San Francisco. To enable everyone to get the most out of this exciting new technology, Crown Bioscience has peeled away the Layars of augmented reality to briefly explain what it is all about and how best to use it.

Read more

June 17, 2014

Aspects of ASCO


Crown Bioscience attended the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago this month, the theme of which was Science and Society. As well as manning a booth incorporating the latest layar technology, Crown Bioscience also reviewed the best of the clinical oncology research on display. A hot topic at this year’s conference was research and clinical trials on anti-PD-1 agents in metastatic melanoma.

Read more

An alarming new study has shown that more than one in three adults in England is on the verge of developing type 2 diabetes. The number of prediabetic people in England has tripled in only 8 years, and without intervention is likely to result in a sharp increase in the number of people living with, and being treated for, diabetes and its related complications.

Read more

In 2012 the World Health Organization ranked ischemic heart disease as the leading cause of death worldwide. Stroke, diabetes mellitus, and hypertensive heart disease also made the top ten list of killer diseases. There is a growing need for new treatments in cardiovascular and metabolic disease (CVMD), yet translational research is often not as fruitful as it should be, with drug development programs relying on poorly predictive rodent models. Non-human primate (NHP) models have the advantage of being much more similar to humans, from their genetics and biochemistry to their physiological and metabolic systems. This increases the predictive power of NHP models, and makes them highly...

Read more

The daily routine of insulin injections faced by the tens of millions of people with diabetes in the US could be about to undergo a major change. The FDA are currently deciding on whether to approve MannKind’s Afrezza®, which could be the first inhaled insulin therapy available in the US for almost a decade. While inhaled agents should be a promising area for new treatment options in diabetes, the first (and last) approved inhaled insulin Exubera® was removed from the market in 2007 following low sales. Crown Bioscience have taken a look at whether Afrezza really is the breath of fresh air that diabetes treatments needs or whether this therapy will also run out of puff.

Read more